key: cord-0799690-rym61en2
authors: Firestone, Melanie J.; Lorentz, Alexandra J.; Wang, Xiong; Como-Sabetti, Kathryn; Vetter, Sara; Smith, Kirk; Holzbauer, Stacy; Meyer, Stephanie; Ehresmann, Kristin; Danila, Richard; Lynfield, Ruth
title: First Identified Cases of SARS-CoV-2 Variant B.1.1.7 in Minnesota — December 2020–January 2021
date: 2021-02-26
journal: MMWR Morb Mortal Wkly Rep
DOI: 10.15585/mmwr.mm7008e1
sha: 0695e7c3cef0d85b8ff7ce91ee4fae3ca4e89f59
doc_id: 799690
cord_uid: rym61en2

On January 9, 2021, the Minnesota Department of Health (MDH) announced the identification of the SARS-CoV-2 variant of concern (VOC) B.1.1.7, also referred to as 20I/501Y.V1 and VOC 202012/01, in specimens from five persons; on January 25, MDH announced the identification of this variant in specimens from three additional persons. The B.1.1.7 variant, which is reported to be more transmissible than certain other SARS-CoV-2 lineages*,† (1), was first reported in the United Kingdom in December 2020 (1). As of February 14, 2021, a total of 1,173 COVID-19 cases of the B.1.1.7 variant had been identified in 39 U.S. states and the District of Columbia (2). Modeling data suggest that B.1.1.7 could become the predominant variant in the United States in March 2021 (3).

* https://www.medrxiv.org/content/10.1101/2020.12.30.20249034v1.full.pdf † https://www.biorxiv.org/content/10.1101/2020.12.14.422555v3.full.pdf § https://virological.org/t/tracking-sars-cov-2-voc-202012-01-lineage-b-1-1-7dissemination-in-portugal-insights-from-nationwide-rt-pcr-spike-gene-dropout-data/600 SARS-CoV-2 surveillance system. ¶ The eight specimens were collected during December 18, 2020-January 11, 2021, from eight Minnesota residents in five counties in the Minneapolis-St. Paul metropolitan area. Seven persons were interviewed after receiving positive SARS-CoV-2 test results; after those with the B.1.1.7 variant were identified, MDH case investigators recontacted the patients to obtain additional information on exposures and close contacts. Six of the eight patients were successfully contacted, including one who had not been interviewed previously. This activity was reviewed by CDC and was conducted consistent with applicable federal law and policy.** The eight persons from whom the specimens were collected ranged in age from 15 to 41 years. Three persons had a history of international travel during the 14 days before illness onset, including two who traveled to West Africa travel to the United Kingdom, although three persons traveled internationally and three persons traveled domestically in the 14 days before illness onset or specimen collection, including one who received a positive test result before returning to Minnesota. Identification of this variant in Minnesota, a variant that epidemiologic and genomic evidence suggests has increased transmissibility, highlights the importance of mitigation measures such as mask use, physical distancing, avoiding crowds and poorly ventilated indoor spaces, isolation of persons with diagnosed COVID-19, quarantine of close contacts of persons with COVID-19, † † and adherence to CDC travel guidance § § to slow transmission. As SARS-CoV-2 continues to evolve, timely genomic surveillance and disease mitigation strategies will be critical for monitoring variant emergence and protecting public health.

Investigation of novel SARS-COV-2 variant: variant of concern 202012/01. London, United Kingdom: Public Health England

US Department of Health and Human Services, CDC; 2021

Emergence of SARS-CoV-2 B.1.1.7 lineage-United States